Literature DB >> 16543738

Experiences with nonfunctioning neuroendocrine neoplasms of the pancreas.

Chang Moo Kang1, Kyung Sik Kim, Jin Sub Choi, Woo Jung Lee, Byong Ro Kim.   

Abstract

AIM: We present our experiences in the treatment of nonfunctioning neuroendocrine neoplasms of the pancreas to define the natural history and to suggest proper management.
METHOD: From August 1993 to June 2005, the medical records of 19 patients with the diagnosis of nonfunctioning neuroendocrine (islet cell) neoplasms of the pancreas were retrospectively reviewed with respect to patient characteristics, characteristics of neoplasms, surgical procedures, and long-term outcomes in the Yonsei University Medical Center, Seoul, Korea.
RESULTS: The median age of the patients (10 males and 9 females) was 51 years. Abdominal pain and discomfort (58%) were the most frequent symptoms. Tumors with a median size of 3.5 cm were noted in the head of the pancreas in 9 patients and in the body or in the tail of the pancreas in 10 patients. Thirteen patients (68%) had neoplasms with malignant features. Twelve patients (63%) underwent surgical resection, and curative resection was performed in 10 patients (53%). Unresectable neoplasms (p=0.0055), distant metastases (p=0.0124), and macroinvasion to adjacent organs (p=0.024) had significantly adverse effects on the mean survival. Neither palliative surgery nor adjuvant chemoradiation therapy seemed to be effective.
CONCLUSIONS: Early detection of nonfunctioning neuroendocrine neoplasms of the pancreas is important, and curative resection should be attempted for a good prognosis. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 16543738     DOI: 10.1159/000092011

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  7 in total

Review 1.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

2.  Non-functioning, malignant pancreatic neuroendocrine tumour (PNET): a rare entity during pregnancy.

Authors:  Carsten H Kamphues; Christoph Röcken; Peter Neuhaus; Ulf P Neumann
Journal:  Langenbecks Arch Surg       Date:  2008-05-30       Impact factor: 3.445

3.  Laparoscopic enucleation of a nonfunctioning neuroendocrine tumor of the pancreas.

Authors:  Chang Moo Kang; Kwang Gil Lee; Ju Yeon Pyo; Sung Whan Lee; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee; Byong Ro Kim
Journal:  Yonsei Med J       Date:  2008-10-31       Impact factor: 2.759

4.  Minimally invasive vs open pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Juwan Kim; Ho Kyoung Hwang; Woo Jung Lee; Chang Moo Kang
Journal:  World J Gastrointest Oncol       Date:  2020-10-15

5.  Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.

Authors:  Li-Ming Zhu; Laura Tang; Xin-Wei Qiao; Edward Wolin; Nicholas N Nissen; Deepti Dhall; Jie Chen; Lin Shen; Yihebali Chi; Yao-Zong Yuan; Qi-Wen Ben; Bin Lv; Ya-Ru Zhou; Chun-Mei Bai; Jie Chen; Yu-Li Song; Tian-Tian Song; Chong-Mei Lu; Run Yu; Yuan-Jia Chen
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 6.  Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review.

Authors:  Anneke P J Jilesen; Casper H J van Eijck; K H in't Hof; S van Dieren; Dirk J Gouma; Els J M Nieveen van Dijkum
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

7.  Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas.

Authors:  Young Jin Yoo; Seok Jeong Yang; Ho Kyoung Hwang; Chang Moo Kang; Hogeun Kim; Woo Jung Lee
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.